Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment

Leong Lee; Ross Campbell; Michaela Scheuermann-Freestone; Rachel Taylor; Prasad Gunaruwan; Lynne Williams; Houman Ashrafian; John Horowitz; Alan G. Fraser; Kieran Clarke; Michael Frenneaux

doi:10.1161/CIRCULATIONAHA.105.551457

Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment

Leong Lee, Ross Campbell, Michaela Scheuermann-Freestone, Rachel Taylor, Prasad Gunaruwan, Lynne Williams, Houman Ashrafian, John Horowitz, Alan G. Fraser, Kieran Clarke, Michael Frenneaux

Research output: Contribution to journal › Article › peer-review

316 Citations (SciVal)

Abstract

Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.

Original language	English
Pages (from-to)	3280-3288
Number of pages	9
Journal	Circulation
Volume	112
Issue number	21
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.105.551457
Publication status	Published - 22 Nov 2005

Keywords

Aged
Cardiovascular Agents
Chronic Disease
Echocardiography, Stress
Fatty Acids
Female
Glucose
Heart Failure
Humans
Male
Middle Aged
Myocardial Ischemia
Myocardium
Oxygen Consumption
Perhexiline
Quality of Life
Stroke Volume
Treatment Outcome

Access to Document

10.1161/CIRCULATIONAHA.105.551457

Cite this

Lee, L., Campbell, R., Scheuermann-Freestone, M., Taylor, R., Gunaruwan, P., Williams, L., Ashrafian, H., Horowitz, J., Fraser, A. G., Clarke, K., & Frenneaux, M. (2005). Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation, 112(21), 3280-3288. https://doi.org/10.1161/CIRCULATIONAHA.105.551457

@article{a2adc78649354353a8b558cd01c17f38,

title = "Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment",

abstract = "Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.",

keywords = "Aged, Cardiovascular Agents, Chronic Disease, Echocardiography, Stress, Fatty Acids, Female, Glucose, Heart Failure, Humans, Male, Middle Aged, Myocardial Ischemia, Myocardium, Oxygen Consumption, Perhexiline, Quality of Life, Stroke Volume, Treatment Outcome",

author = "Leong Lee and Ross Campbell and Michaela Scheuermann-Freestone and Rachel Taylor and Prasad Gunaruwan and Lynne Williams and Houman Ashrafian and John Horowitz and Fraser, {Alan G.} and Kieran Clarke and Michael Frenneaux",

year = "2005",

month = nov,

day = "22",

doi = "10.1161/CIRCULATIONAHA.105.551457",

language = "English",

volume = "112",

pages = "3280--3288",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott, Williams and Wilkins",

number = "21",

}

Lee, L, Campbell, R, Scheuermann-Freestone, M, Taylor, R, Gunaruwan, P, Williams, L, Ashrafian, H, Horowitz, J, Fraser, AG, Clarke, K & Frenneaux, M 2005, 'Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment', Circulation, vol. 112, no. 21, pp. 3280-3288. https://doi.org/10.1161/CIRCULATIONAHA.105.551457

TY - JOUR

T1 - Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment

AU - Lee, Leong

AU - Campbell, Ross

AU - Scheuermann-Freestone, Michaela

AU - Taylor, Rachel

AU - Gunaruwan, Prasad

AU - Williams, Lynne

AU - Ashrafian, Houman

AU - Horowitz, John

AU - Fraser, Alan G.

AU - Clarke, Kieran

AU - Frenneaux, Michael

PY - 2005/11/22

Y1 - 2005/11/22

N2 - Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.

AB - Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.

KW - Aged

KW - Cardiovascular Agents

KW - Chronic Disease

KW - Echocardiography, Stress

KW - Fatty Acids

KW - Female

KW - Glucose

KW - Heart Failure

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Ischemia

KW - Myocardium

KW - Oxygen Consumption

KW - Perhexiline

KW - Quality of Life

KW - Stroke Volume

KW - Treatment Outcome

U2 - 10.1161/CIRCULATIONAHA.105.551457

DO - 10.1161/CIRCULATIONAHA.105.551457

M3 - Article

C2 - 16301359

VL - 112

SP - 3280

EP - 3288

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 21

ER -